The Sable Team

The Sable Team

The Sable Team

Nice to meet you.

Nice to meet you.

Nice to meet you.

At Sable, we unite multidisciplinary talents and insights, all dedicated to the pursuit of advancing drug safety. Our culture is founded on trust, clarity, and teamwork, driving innovation in the realm of biopharmaceuticals. Together, we're forging new paths in patient care and medication efficacy.

At Sable, we unite multidisciplinary talents and insights, all dedicated to the pursuit of advancing drug safety. Our culture is founded on trust, clarity, and teamwork, driving innovation in the realm of biopharmaceuticals. Together, we're forging new paths in patient care and medication efficacy.

At Sable, we unite multidisciplinary talents and insights, all dedicated to the pursuit of advancing drug safety. Our culture is founded on trust, clarity, and teamwork, driving innovation in the realm of biopharmaceuticals. Together, we're forging new paths in patient care and medication efficacy.

Josh Almond-Thynne

Josh Almond-Thynne

Co-Founder

Co-Founder

Prior to founding Sable, Josh helped deliver two pre-clinical candidates at BenevolentAI as a medicinal chemist. He pioneered the use of unstructured data in medicinal chemistry.

Josh gained his Ph.D. in organic chemistry from Imperial College London, and has held research positions at the University of Oxford, CSIRO, and Boehringer Ingelheim.

Prior to founding Sable, Josh helped deliver two pre-clinical candidates at BenevolentAI as a medicinal chemist. He pioneered the use of unstructured data in medicinal chemistry.

Josh gained his Ph.D. in organic chemistry from Imperial College London, and has held research positions at the University of Oxford, CSIRO, and Boehringer Ingelheim.

Alex de Giorgio

Alex de Giorgio

Co-Founder

Co-Founder

Prior to founding Sable, Alex worked at BenevolentAI, leading multiple disease deployments, pioneering new methods for relationship extraction, and building and launching a drug repositioning platform.


He holds a BSc in Biology from the University of Oxford and a PhD from Imperial College, with his publications gaining over 1000 citations.

Prior to founding Sable, Alex worked at BenevolentAI, leading multiple disease deployments, pioneering new methods for relationship extraction, and building and launching a drug repositioning platform.


He holds a BSc in Biology from the University of Oxford and a PhD from Imperial College, with his publications gaining over 1000 citations.

Olly Oechsle

Olly Oechsle

Chief Technology Officer

Chief Technology Officer

Prior to joining Sable, Olly spent eight years at BenevolentAI working on applications, data pipelines and Natural Language Processing (NLP) techniques, as VP of Product Engineering.


Olly previously worked in Engineering and User Experience for UK media organisations including the Telegraph and the Guardian. He holds a PhD in Computer Vision and Machine Learning.

Clare West

Clare West

Computational Biology Lead

Computational Biology Lead

Prior to joining Sable, Clare led the development of AI-enabled target identification products at BenevolentAI, translating biological data into actionable insights for drug discovery scientists.


Clare holds a DPhil in Protein Informatics from the University of Oxford and has held research positions at the Centre for Medicines Discovery, University of Oxford, and Open Targets.

Camille Petri

Camille Petri

Data Science Lead

Data Science Lead

Prior to joining Sable, Camille worked in data science and machine learning roles within healthcare, spanning industry and academia, and holding positions at Imperial College London, Eli Lilly, IQVIA, and Parexel.


He holds a medical degree with a specialisation in Public Health, as well as Master's degrees in Applied Mathematics and Public health from University Paris-Cité and University Paris-Saclay respectively.

© 2024 SableBio Limited (Company number 15084894)

© 2024 SableBio Limited (Company number 15084894)

© 2024 SableBio Limited (Company number 15084894)